Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 11/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.67 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609515 | 1.00 | LMNA (0.68) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL12609477 | 0.97 | LMNA (0.63) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL4418795 | 0.90 | LMNA (0.55) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL4418793 | 0.90 | LMNA (0.55) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL12101822 | 0.90 | LMNA (0.55) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL12609480 | 0.81 | MAPT (0.55) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL12609495 | 0.80 | MAPT (0.49) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL12609517 | 0.79 | MAPT (0.76) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL12651726 | 0.79 | MAPT (0.70) | LMNAMAPTL3MBTL1KMT2AMEN1 | |
| SCHEMBL13538717 | 0.79 | MAPT (0.67) | LMNAMAPTL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227018-B1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | UNIV VIRGINIA COMMONWEALTH (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10000453-B2 | Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170362181-A1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2017-12-21 | — | — | US | disclosed |
| US-7262326-B2 | Process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-08-28 | — | — | US | disclosed |
| EP-1797030-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF INDANYLAMINE OR AMINOTETRALIN DERIVATIVES AND NOVEL INTERMEDIATES | Teva Pharmaceuticals USA, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006029135-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF INDANYLAMINE OR AMINOTETRALIN DERIVATIVES AND NOVEL INTERMEDIATES | TEVA PHARMACEUTICAL USA, INC (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052639-A1 | Process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates | TEVA PHARMACEUTICALS USA, INC. (US) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362181-A1 | CHELATION DIRECTED C-H ACTIVATION REACTIONS CATALYZED BY SOLID-SUPPORTED PALLADIUM(II) CATALYSTS | WASF2, SCO2, SOD1 | LMNA 3565/4885MAPT 2594/4885L3MBTL1 1181/4885 |
| US-10000453-B2 | Chelation directed C—H activation reactions catalyzed by solid-supported palladium(II) catalysts | WASF2, SOD1, CD274 | LMNA 3454/4885MAPT 2583/4885L3MBTL1 1229/4885 |
| US-20060052639-A1 | Process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates | IDO1, INMT, TDO2 | LMNA 4050/4885MAPT 1649/4885L3MBTL1 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.